Pretreatment characteristics and clinical outcome of acute promyelocytic leukaemia patients according to the PML-RAR alpha isoforms: a study of the PETHEMA group.
González M, Barragán E, Bolufer P, Chillón C, Colomer D, Borstein R, Calasanz MJ, Gómez-Casares MT, Villegas A, Marugán I, Román J, Martín G, Rayón C, Debén G, Tormo M, Díaz-Mediavilla J, Esteve J, González-San Miguel J, Rivas C, Pérez-Equiza K, García-Sanz R, Capote FJ, Ribera JM, Arias J, León A, Sanz MA; Spanish Programme for the Study and Treatment of Haematological Malignancies (PETHEMA) Group.
González M, et al. Among authors: calasanz mj.
Br J Haematol. 2001 Jul;114(1):99-103. doi: 10.1046/j.1365-2141.2001.02915.x.
Br J Haematol. 2001.
PMID: 11472351
Free article.
Clinical Trial.